Back to top
more

ImmunoPrecise Antibodies (IPA)

(Delayed Data from NSDQ)

$1.29 USD

1.29
73,036

+0.03 (2.38%)

Updated May 10, 2024 04:00 PM ET

After-Market: $1.35 +0.06 (4.65%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (158 out of 250)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates

ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of 0% and 3.93%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?

New Strong Buy Stocks for February 7th

AMSC, META, CLX, IPA and KMPR have been added to the Zacks Rank #1 (Strong Buy) List on February 7, 2023.

New Strong Buy Stocks for February 5th

EZPW, MOD, IPA, WDC and OSK have been added to the Zacks Rank #1 (Strong Buy) List on February 5, 2023.

Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates

Phreesia (PHR) delivered earnings and revenue surprises of 19.44% and 2.56%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?

New Strong Buy Stocks for October 23rd

MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.

ImmunoPrecise Antibodies Ltd. (IPA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

ImmunoPrecise Antibodies Ltd. (IPA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Tops Revenue Estimates

ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of 35.29% and 7.09%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?

InnovAge Holding Corp. (INNV) Reports Q4 Loss, Tops Revenue Estimates

InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -200% and 1.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Phreesia (PHR) Reports Q2 Loss, Tops Revenue Estimates

Phreesia (PHR) delivered earnings and revenue surprises of 9.33% and 1.22%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Lags Revenue Estimates

ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of -16.67% and 6.19%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Axonics Modulation Technologies (AXNX) Surpasses Q4 Earnings and Revenue Estimates

Axonics (AXNX) delivered earnings and revenue surprises of 104.35% and 0.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 4.24% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?